highlight eight name univers earn believ upsid
estim like mdso believ consensu revenu
estim risk alreadi offer guidanc would
look buy athn pullback provid answer investor
look
includ quarter-to-quart volatil
book pressur provid reimburs
affect budget major regulatori
mdso overweight expect strong guidanc near
revenu target share mdso languish sinc earn report
disappoint guid departur mike capon insid sell
guid relat time renew trial start departur mike capon
like result third wheel close senior manag
team insid sell done one fell swoop program
expir earlier year believ stock price risk
under-perform market past day believ catalyst stock
revenu guidanc ahead street consensu manag back
revenu goal order achiev revenu acceler
current reflect consensu estim believ mdso
strong competit advantag edc vendor offer
machine-learn power risk-bas monitor solut capabl
differenti edc-onli vendor estim revenue/ep
respect vs consensu respect
overweight book momentum drive strong revenu ep
guidanc vocera releas full year book result believ
acceler book growth driven
sever factor one increas valu proposit platform
engag solut fulli integr platform increas averag
deal size client contract broader roll-out capabl
three product year va/dod contract believ much book
translat revenu growth give us confid above-consensu
revenu estim also believ outlook profit
strong compani consist call increment ebitda
margin upon profit organ basi acceler profit
also catalyst stock estim revenue/ep
respect vs consensu respect
overweight new pbm contract may drive upsid estim earli
year tabula rasa announc contract new undisclos pbm bring
overal market share within medicar part believ contract could
driver upsid consensu revenu estim meaning
ipo highlight financi press believ upsid full year
revenu estim could take number stock higher beyond one pbm
contract believ enhanc medic therapi manag emtm servic
garner widespread attent emtm pilot move year two
expand footprint within pilot throughout medicar part plan
estim revenue/ep respect in-lin consensu
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
overweight expect littl fanfar pre-announc result guidanc
pre-announc result guidanc dont expect surpris
report earn februari januari compani announc revenu
approxim vs pjc estim ebitda visit
preliminari outlook call revenu ebitda per
analyst day expect receiv granular oper metric
dial model upon receipt metric thesi remain stock
mainstream telehealth drive membership visit organ revenu growth
effect alloc capit like continu drive opportun inorgan
growth remain bullish name remaind year likelihood
mainstream drive upsid guidanc reiter price target
overweight va time new ceo tax rate unansw question need
answer take stock higher overweight rate share
price target look answer question potenti take ep estim
remain steadfast target ebitda multipl trade call
add posit get answer question pullback dont
expect updat va time believ deal himss earli march like given
week delay impos secretari veteran affair david shulkin reason delay
due need spec interoper pjc healthcar confer jeff townsend
commit deliv need interoper high confid
overcom hurdl sign contract give us reason potenti turn posit
estim also look meet new ceo also wait
himss final upward bia ep due lower tax rate could also give
us reason potenti take estim book guidanc achiev
announc itwork contract adventist report februari
close estim revenue/ep respect in-lin consensu view
athn overweight non-committ time guidanc strong flu season
benefit guid delay analyst day februari compani yet said
whether offer guidanc earn call analyst day februari
guidanc like impact stock result plu side
believ strong flu season benefit guidanc rememb athn get paid
provid get paid week lag mani unansw question remain
churn inpati strategi growth lever like tabl analyst
day estim revenue/ep respect vs consensu
underweight remain cautiou growth outlook continu cautiou
growth prospect inovalon remain street low revenu latest datapoint
support thesi independ cross top inovalon custom invest
lumiata artifici intellig platform identifi caregap independ list
revenu custom year past believ independ remain custom
inovalon aspect busi made equiti invest lumiata
board observ roll platform caregap analysi believ
anoth datapoint support thesi custom attrit risk inovalon
pressur revenu growth past sever year quarter estim revenue/
ep respect vs in-lin consensu view
neutral cautiou guidanc sever occas manag steer
street revenu growth rate middl long term target
page
estim reflect street consensu revenu growth therefor remain
somewhat cautiou stock likelihood compani guid consensu view
estim reflect elong adopt cycl compani new xt platform
check omcl top custom provid favor review xt platform
indic intent remain cabinet throughout use life
point upgrad cabinet case-by-cas basi xt believ bull
case argu rapid adopt cycl posit side earn like
benefit lower tax rate howev believ upsid alreadi price stock
estim revenue/ep respect vs street consensu
page
